Clinical Trials

Inclusion Criteria:

• Unimpaired APOE e4/4 homozygotes age 65-75 and APOE e3/4 heterozygotes age 75-85 for the preclinical AD subset and age, sex, and education matched APOE e4 noncarriers for the unaffected controls. 
• Biomarker confirmation for preclinical diagnosis will be utilized to the extent possible (a subset of 130 members of our cohort have undergone amyloid-PET resulting in approximately 45 who are amyloid positive).

Exclusion Criteria:

• Previous stroke.
• Severe head injury.
• Craniotomy.
• Any other potentially confounding neurologic illness (typically anything that causes structural brain damage). 
• Psychoactive medication use will not be an absolute exclusionary criterion in patients with moderate to severe dementia but patients who are relatively drug-free will be prioritized to the extent they are available within the study period. 
• Psychoactive drug use will be exclusionary in the prospectively obtained clinical patients.